journal

Lancet Oncology

journal
https://read.qxmd.com/read/32224306/lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer-a-single-arm-open-label-phase-2-basket-trial
#1
José Trigo, Vivek Subbiah, Benjamin Besse, Victor Moreno, Rafael López, María Angeles Sala, Solange Peters, Santiago Ponce, Cristian Fernández, Vicente Alfaro, Javier Gómez, Carmen Kahatt, Ali Zeaiter, Khalil Zaman, Valentina Boni, Jennifer Arrondeau, Maite Martínez, Jean-Pierre Delord, Ahmad Awada, Rebecca Kristeleit, Maria Eugenia Olmedo, Luciano Wannesson, Javier Valdivia, María Jesús Rubio, Antonio Anton, John Sarantopoulos, Sant P Chawla, Joaquín Mosquera-Martinez, Manolo D'Arcangelo, Armando Santoro, Victor M Villalobos, Jacob Sands, Luis Paz-Ares
BACKGROUND: Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic transcription. In this phase 2 study, we evaluated the acti and safety of lurbinectedin in patients with SCLC after failure of platinum-based chemotherapy. METHODS: In this single-arm, open-label, phase 2 basket trial, we recruited patients from 26 hospitals in six European countries and the USA...
March 27, 2020: Lancet Oncology
https://read.qxmd.com/read/32224305/new-opportunities-in-a-challenging-disease-lurbinectedin-for-relapsed-small-cell-lung-cancer
#2
Oscar Arrieta, Zyanya Lucia Zatarain-Barrón, Andrés F Cardona
No abstract text is available yet for this article.
March 27, 2020: Lancet Oncology
https://read.qxmd.com/read/32222155/new-therapy-for-children-with-plexiform-neurofibromas
#3
Elizabeth Gourd
No abstract text is available yet for this article.
March 26, 2020: Lancet Oncology
https://read.qxmd.com/read/32220660/challenges-posed-by-covid-19-to-children-with-cancer
#4
LETTER
Rishi S Kotecha
No abstract text is available yet for this article.
March 25, 2020: Lancet Oncology
https://read.qxmd.com/read/32220659/the-official-french-guidelines-to-protect-patients-with-cancer-against-sars-cov-2-infection
#5
Benoit You, Alain Ravaud, Anne Canivet, Gérard Ganem, Philippe Giraud, Rosine Guimbaud, Laure Kaluzinski, Ivan Krakowski, Didier Mayeur, Thomas Grellety, Jean-Pierre Lotz
No abstract text is available yet for this article.
March 25, 2020: Lancet Oncology
https://read.qxmd.com/read/32213340/quality-of-life-in-patients-with-lung-cancer-the-way-forward
#6
Maria Lucia Reale, Massimo Di Maio
No abstract text is available yet for this article.
March 23, 2020: Lancet Oncology
https://read.qxmd.com/read/32213339/cancer-care-in-the-time-of-covid-19
#7
Talha Khan Burki
No abstract text is available yet for this article.
March 23, 2020: Lancet Oncology
https://read.qxmd.com/read/32213338/psychometric-properties-of-the-updated-eortc-module-for-assessing-quality-of-life-in-patients-with-lung-cancer-qlq-lc29-an-international-observational-field-study
#8
Michael Koller, Omar Shamieh, Marianne J Hjermstad, Kjersti Hornslien, Teresa Young, Tara Chalk, Georgios Ioannidis, Amelie Harle, Colin D Johnson, Krzysztof A Tomaszewski, Samantha Serpentini, Monica Pinto, Lotte van der Weijst, Annelies Janssens, Ofir Morag, Wei-Chu Chie, Juan I Arraras, Cecilia Pompili, Wolfgang Jungraithmayr, Marlene Hechtner, Despina Katsochi, Karolina Müller, Laura Gräfenstein, Christian Schulz, Andrew Bottomley
BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the first EORTC module developed for use in international clinical trials. Since its publication in 1994, major treatment advances with possible effects on QOL have occurred. These changes called for an update of the module and its international psychometric validation. We aimed to investigate the scale structure and psychometric properties of the updated lung cancer module, QLQ-LC29, in patients with lung cancer...
March 23, 2020: Lancet Oncology
https://read.qxmd.com/read/32203699/fgfr-inhibitors-for-advanced-cholangiocarcinoma
#9
Tian Yang, Lei Liang, Ming-Da Wang, Feng Shen
No abstract text is available yet for this article.
March 20, 2020: Lancet Oncology
https://read.qxmd.com/read/32203698/pemigatinib-for-previously-treated-locally-advanced-or-metastatic-cholangiocarcinoma-a-multicentre-open-label-phase-2-study
#10
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy, Do-Youn Oh, Efrat Dotan, Daniel V Catenacci, Eric Van Cutsem, Tao Ji, Christine F Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel
BACKGROUND: Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements. METHODS: In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations...
March 20, 2020: Lancet Oncology
https://read.qxmd.com/read/32203697/quality-of-life-after-breast-conserving-surgery-for-women-with-non-low-risk-ductal-carcinoma-in-situ
#11
John R Benson
No abstract text is available yet for this article.
March 20, 2020: Lancet Oncology
https://read.qxmd.com/read/32203696/quality-of-life-after-breast-conserving-therapy-and-adjuvant-radiotherapy-for-non-low-risk-ductal-carcinoma-in-situ-big-3-07-trog-07-01-2-year-results-of-a-randomised-controlled-phase-3-trial
#12
Madeleine T King, Emma K Link, Tim J Whelan, Ivo A Olivotto, Ian Kunkler, Antonia Helen Westenberg, Guenther Gruber, Penny Schofield, Boon H Chua
BACKGROUND: BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and whole breast radiotherapy. Here, we report the effects of diagnosis and treatment on health-related quality of life (HRQOL) at 2 years. METHODS: The BIG 3-07/TROG 07.01 trial is ongoing at 118 hospitals in 11 countries...
March 20, 2020: Lancet Oncology
https://read.qxmd.com/read/32192574/nivolumab-in-paediatric-cancer-children-are-not-little-adults
#13
Jaume Mora, Shakeel Modak
No abstract text is available yet for this article.
March 16, 2020: Lancet Oncology
https://read.qxmd.com/read/32192573/nivolumab-in-children-and-young-adults-with-relapsed-or-refractory-solid-tumours-or-lymphoma-advl1412-a-multicentre-open-label-single-arm-phase-1-2-trial
#14
Kara L Davis, Elizabeth Fox, Melinda S Merchant, Joel M Reid, Rachel A Kudgus, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall
BACKGROUND: Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and antitumour activity in children and young adults with recurrent or refractory non-CNS solid tumours or lymphoma. METHODS: We did a multicentre, open-label, single-arm, dose-confirmation and dose-expansion, phase 1-2 trial in 23 hospitals in the USA...
March 16, 2020: Lancet Oncology
https://read.qxmd.com/read/32171429/imaging-based-target-volume-reduction-in-chemoradiotherapy-for-locally-advanced-non-small-cell-lung-cancer-pet-plan-a-multicentre-open-label-randomised-controlled-trial
#15
Ursula Nestle, Tanja Schimek-Jasch, Stephanie Kremp, Andrea Schaefer-Schuler, Michael Mix, Andreas Küsters, Marco Tosch, Thomas Hehr, Susanne Martina Eschmann, Yves-Pierre Bultel, Peter Hass, Jochen Fleckenstein, Alexander Thieme, Marcus Stockinger, Karin Dieckmann, Matthias Miederer, Gabriele Holl, H Christian Rischke, Eleni Gkika, Sonja Adebahr, Jochem König, Anca-Ligia Grosu
BACKGROUND: With increasingly precise radiotherapy and advanced medical imaging, the concept of radiotherapy target volume planning might be redefined with the aim of improving outcomes. We aimed to investigate whether target volume reduction is feasible and effective compared with conventional planning in the context of radical chemoradiotherapy for patients with locally advanced non-small-cell lung cancer. METHODS: We did a multicentre, open-label, randomised, controlled trial (PET-Plan; ARO-2009-09) in 24 centres in Austria, Germany, and Switzerland...
March 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32171428/preoperative-endocrine-therapy-for-ductal-carcinoma-in-situ
#16
Elizabeth Gourd
No abstract text is available yet for this article.
March 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32171427/is-her2-positive-metastatic-breast-cancer-still-an-incurable-disease
#17
Matteo Lambertini, Ines Vaz-Luis
No abstract text is available yet for this article.
March 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32171426/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer-cleopatra-end-of-study-results-from-a-double-blind-randomised-placebo-controlled-phase-3-study
#18
Sandra M Swain, David Miles, Sung-Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark C Benyunes, Javier Cortés
BACKGROUND: CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. In the primary analysis and subsequent reports, progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group. Here, we report the end-of-study analysis of CLEOPATRA. METHODS: This was a double-blind, randomised, placebo-controlled, phase 3 trial that was done at 204 centres in 25 countries...
March 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32171425/less-is-more-in-radiotherapy-target-volume-planning-lessons-from-the-pet-plan-trial
#19
Corinne Faivre-Finn
No abstract text is available yet for this article.
March 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32171071/rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-combined-with-high-dose-methotrexate-plus-intrathecal-chemotherapy-for-newly-diagnosed-intravascular-large-b-cell-lymphoma-primeur-ivl-a-multicentre-single-arm-phase-2-trial
#20
Kazuyuki Shimada, Motoko Yamaguchi, Yoshiko Atsuta, Kosei Matsue, Keijiro Sato, Shigeru Kusumoto, Hirokazu Nagai, Jun Takizawa, Noriko Fukuhara, Koji Nagafuji, Kana Miyazaki, Eiichi Ohtsuka, Masataka Okamoto, Yasumasa Sugita, Toshiki Uchida, Satoshi Kayukawa, Atsushi Wake, Daisuke Ennishi, Yukio Kondo, Tohru Izumi, Yoshihiro Kin, Kunihiro Tsukasaki, Daigo Hashimoto, Masaaki Yuge, Atsumi Yanagisawa, Yachiyo Kuwatsuka, Satoko Shimada, Yasufumi Masaki, Nozomi Niitsu, Hitoshi Kiyoi, Ritsuro Suzuki, Takashi Tokunaga, Shigeo Nakamura, Tomohiro Kinoshita
BACKGROUND: Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy for patients with previously untreated IVLBCL. METHODS: PRIMEUR-IVL is a multicentre, single-arm, phase 2 trial at 22 hospitals in Japan...
March 11, 2020: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"